Difei Yang
Stock Analyst at Mizuho
(1.81)
# 3,053
Out of 4,835 analysts
36
Total ratings
28.12%
Success rate
4.79%
Average return
Main Sectors:
Stocks Rated by Difei Yang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKBA Akebia Therapeutics | Downgrades: Neutral | $6 → $2 | $2.61 | -23.37% | 4 | Mar 31, 2022 | |
| BLUE bluebird bio | Maintains: Buy | $580 → $460 | $4.97 | +9,155.53% | 3 | Sep 22, 2021 | |
| NVCR NovoCure | Maintains: Neutral | $229 → $200 | $17.89 | +1,017.94% | 6 | Jul 30, 2021 | |
| CASI CASI Pharmaceuticals | Initiates: Buy | $38 | $1.87 | +1,932.09% | 1 | Apr 26, 2021 | |
| FGEN FibroGen | Downgrades: Neutral | $29 | $0.31 | +9,377.12% | 4 | Apr 7, 2021 | |
| QURE uniQure | Upgrades: Buy | $52 | $13.70 | +279.56% | 4 | Apr 1, 2021 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $158 → $160 | $36.43 | +339.20% | 2 | Feb 26, 2021 | |
| XERS Xeris Biopharma Holdings | Maintains: Buy | $18 → $14 | $4.88 | +186.89% | 4 | Apr 23, 2020 | |
| NKTR Nektar Therapeutics | Upgrades: Buy | $21 → $35 | $0.69 | +5,009.49% | 4 | Feb 3, 2020 | |
| BOLD Boundless Bio | Upgrades: Buy | n/a | $1.65 | - | 2 | Aug 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $28 | $8.89 | +214.96% | 1 | Feb 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $1.97 | +1,321.32% | 1 | Sep 27, 2017 |
Akebia Therapeutics
Mar 31, 2022
Downgrades: Neutral
Price Target: $6 → $2
Current: $2.61
Upside: -23.37%
bluebird bio
Sep 22, 2021
Maintains: Buy
Price Target: $580 → $460
Current: $4.97
Upside: +9,155.53%
NovoCure
Jul 30, 2021
Maintains: Neutral
Price Target: $229 → $200
Current: $17.89
Upside: +1,017.94%
CASI Pharmaceuticals
Apr 26, 2021
Initiates: Buy
Price Target: $38
Current: $1.87
Upside: +1,932.09%
FibroGen
Apr 7, 2021
Downgrades: Neutral
Price Target: $29
Current: $0.31
Upside: +9,377.12%
uniQure
Apr 1, 2021
Upgrades: Buy
Price Target: $52
Current: $13.70
Upside: +279.56%
Sarepta Therapeutics
Feb 26, 2021
Maintains: Buy
Price Target: $158 → $160
Current: $36.43
Upside: +339.20%
Xeris Biopharma Holdings
Apr 23, 2020
Maintains: Buy
Price Target: $18 → $14
Current: $4.88
Upside: +186.89%
Nektar Therapeutics
Feb 3, 2020
Upgrades: Buy
Price Target: $21 → $35
Current: $0.69
Upside: +5,009.49%
Boundless Bio
Aug 8, 2018
Upgrades: Buy
Price Target: n/a
Current: $1.65
Upside: -
Feb 13, 2018
Initiates: Neutral
Price Target: $28
Current: $8.89
Upside: +214.96%
Sep 27, 2017
Initiates: Buy
Price Target: $28
Current: $1.97
Upside: +1,321.32%